Navigation Links
Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Date:5/21/2009

NANJING, China, May 21 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has applied for two Chinese patents for its flagship product, Cisatracurim besylate, a pre-surgical skeletal muscle relaxant.

The Company has applied to China's State Intellectual Property Office (SIPO) for a Chinese patent for Atracurium's freeze-drying compounds (Application Number 200710127756.2; "Atracurium's freeze-drying compounds"). This patent has already been published and is now awaiting certification.

The Company has also applied to SIPO for a Chinese patent for the preparation for separating and purifying Cisatracurim besylate through HPLC (Application Number 200910028198.3; "The preparation for separating and purifying Cisatracurim besylate through HPLC"). Using this method, the Company will reduce manufacturing costs and improve product quality.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or r
'/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
2. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
3. Sinobiopharma Secures Rights to Seven Key Patents
4. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma, Inc. Appoints New Director of Marketing
7. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Saddam Lawyer Applies for Pardon for Dr Crippen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Livermore, California (PRWEB) October 01, 2014 ... Reyes has assumed the 2014-15 chairmanship of the ... election as vice chair in 2012. , Reyes has ... projects. She joined LLNL in 2001 to pursue her ... analysis of inertial fusion energy power plant designs. Since ...
(Date:10/2/2014)... 02, 2014 Cystic fibrosis (CF) is ... and the gastrointestinal organs. In particular, very thick mucus ... is very difficult to clear, occludes the airways, and ... these patients frequently suffer from chronic biofilm infections, and ... a novel approach to treating the major challenges in ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 IAL ... fourth edition of its report on the markets ... new edition examines the developments encountered in the ... both products. , Full Report With TOC ... the market trends driving the demand. The study ...
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
Breaking Biology Technology:Susana Reyes Assumes Chair of American Nuclear Society Fusion Energy Division 2Synedgen to Present at North American Cystic Fibrosis Conference 2Synedgen to Present at North American Cystic Fibrosis Conference 3Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... a biotechnology company developing peptide therapeutics for metabolic diseases, ... as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from ... President and Late-Stage Therapeutic Group Leader, with responsibility for ... and previously as head of early-stage clinical development programs. ...
... -- an open-source, web-based platform for data-intensive biomedical ... a "cloud computing" resource. A team of researchers ... and molecular biology at Penn State University; Kateryna ... State; and James Taylor from Emory University, developed ...
Cached Biology Technology:Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Rhythm Names Keith M. Gottesdiener Chief Executive Officer 2Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:10/2/2014)... , October 2, 2014 ... Event for payment, identification and mobility which is ... from 4 to 6 November 2014, is proud ... partnership with innovation agency FABERNOVEL.   ... this initiative is to support innovative businesses from ...
(Date:10/2/2014)... SHELTON, Conn. , Oct. 2, 2014 NXT-ID, ... focused on the growing mobile commerce market, announces the airings ... Money and Mad Money. The national ads resumed ... will air October 2 nd and October 3 rd ... The continuing ads that began airing on CNBC ...
(Date:10/2/2014)... CARTES SECURE CONNEXIONS 2014 Conference: A Step Ahead ... SECURE CONNEXIONS 2014 is being held at Paris Nord ... This 29 th  international meeting for the digital security ... together the global community of a constantly evolving sector. ... will set the pace for the event.   ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 2CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4
... in Acta Obstetricia et Gynecologica Scandinavica , a ... and Gynecology, indicate that human error is the most ... monitoring, lack of clinical skills, and failure to obtain ... Norwegian compensation claims following birth asphyxia. In ...
... we wanted to count the number of people in a crowd, ... imprecise, or we could ask each person to pass through a ... for creating a "DNA reader" that is able to detect the ... with integrated graphene transistor. The DNA molecules are diluted in ...
... team has discovered a gene associated with a high ... may be an actual cause of this form of ... "Because asthma is a complex disease, with multiple ... asthma occurring between ages two and six," said co-lead ...
Cached Biology News:Human error most common cause of birth asphyxia 2Graphene nanoribbons for 'reading' DNA 2Novel gene variant found in severe childhood asthma 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Reactivity: Human...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: